{"schema_version":"secwatch.filing_event.v1","accession":"0000937556-23-000193","form_type":"8-K","ticker":"MASI","cik":"0000937556","company_name":"MASIMO CORP","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.093689+00:00","generated_at":"2026-06-12T03:32:46.117706+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Masimo Q2 revenue $455M, EPS $0.29 GAAP; cuts FY guidance to $2.1-2.2B","bullets":["Consolidated revenue $455.3M (healthcare $281.1M, non-healthcare $174.2M); GAAP EPS $0.29, non-GAAP $0.62.","GAAP operating income $29.3M, non-GAAP $58.6M; 64,100 noninvasive tech board shipments.","CEO disappointed; record hospital customer gains but inpatient volumes below expectations.","Updated Q3 2023 revenue guidance $475-525M; full-year revenue $2.1-2.2B (down from prior).","Full-year GAAP EPS guidance $1.91-2.11; non-GAAP $3.35-3.55."],"urls":{"canonical":"https://secwatch.observer/filing/0000937556-23-000193","json":"https://secwatch.observer/filing/0000937556-23-000193.json","markdown":"https://secwatch.observer/filing/0000937556-23-000193.md","text":"https://secwatch.observer/filing/0000937556-23-000193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/937556/000093755623000193/0000937556-23-000193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/937556/000093755623000193/masi-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:32:46.117706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fa2d311383f6b9261782305ebc023756179aac2","claim":"MASIMO CORP reported second quarter of 2023, ended July 1, 2023 results: revenue $455.3 million, net income $15.7 million, or $0.29 per diluted share, EPS $0.29 per diluted share.","evidence_excerpt":"by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Masimo Reports Second Quarter 2023 Financial Results Second Quarter 2023 Highlights • Consolidated revenue was $455.3 million; • Healthcare revenue was $281.1 million; • Non-healthcare revenue was $174.2 million; • GAAP net income per diluted share was $0.29; and • Non-GAAP net income per diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/937556/000093755623000193/0000937556-23-000193-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023, ended July 1, 2023"},{"label":"Revenue","value":"$455.3 million"},{"label":"Net income","value":"$15.7 million, or $0.29 per diluted share"},{"label":"EPS","value":"$0.29 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}